http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
ZhEng, D. W.,Huang, Y. P.,Tang, T. A.,Cui, Q.,Li, A. Z.,Zhou, S. X.,He, Z. J.,Chen, Z.,Zhang, X. J.,Kwor, R. 대한전자공학회 1993 ICVC : International Conference on VLSI and CAD Vol.3 No.1
A novel process for silicon on insulator(SOI) technology has been presented. Single crystal Si is grown by molecular beam epitaxy(MBF) on a porous silicon(PS) system consisting of two layers of PS with different microstructures. Subsequent lateral oxidation converts the structure to SOI wish excellent insulation property. Si islands with a width of 135㎛ and low doping concentration have been achieved.
( L. Wei ),( F. Wang ),( M. Zhang ),( J. Jia ),( A.A. Yakovlev ),( W. Xie ),( E.Z. Burnevich ),( J. Niu ),( Y.J. Jung ),( X. Jiang ),( M. Xu ),( X. Chen ),( Q. Xie ),( J. Li ),( J. Hou ),( H. Tang ),( 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Background/Aims: Treatment-naive GT 1b-infected patients from mainland China, South Korea and Russia were assessed for SVR at follow-up week 12 (SVR12) after receiving daclatasvir (60 mg, QD) and asunaprevir (100 mg, BID) (DCV+ASV). Methods: Patients were randomized 3:1 to receive DCV+ASV (24 weeks; immediate treatment [IM]) or 12 weeks of placebo followed by DCV+ASV (24 weeks; placebo-deferred treatment [PD]). The primary endpoint was to evaluate SVR12 in the IM arm to the historical rate for peginterferon/ribavirin (70%). Secondary endpoints included overall safety and safety comparisons between the treatment arms during the first 12 weeks. Results: 207 patients were randomized to IM (n=155) or PD (n=52); Asian (86%), female (59%), IL28B CC genotype (68%) and median age 49 (range 18-73) years; cirrhosis (13%), HCV RNA ≥6x106 IU/mL (53%). SVR12 in the IM arm was 92% and broadly unaffected by most baseline factors assessed (Figure); SVR12 was higher in patients without (96%) baseline NS5A-L31M/V or Y93H polymorphisms. There were 6 virologic breakthroughs, 6 relapses and 1 detectable HCV RNA at end-of-treatment in the IM arm. Safety was mostly comparable between the two arms during the first 12 weeks. The most frequent adverse events (AEs; ≥5%) during DCV+ASV (24 weeks) treatment in both arms were aminotransferase, bilirubin and INR elevations, hypertension, fatigue and respiratory tract infections; the most frequent treatment-emergent grade 3/4 laboratory abnormalities were aminotransferase (≤4.5%) and hematologic, lipase and total bilirubin abnormalities (≤2%); one patient (IM) discontinued DCV+ASV for aminotransferase elevations, nausea and jaundice (all reversible); one patient PD) discontinued DCV+ASV for a fatal AE unrelated to treatment. Conclusions: These data demonstrate that DCV+ASV is a highly efficacious and well tolerated treatment for treatment-naive HCV GT 1b-infected patients. Those treated immediately with DCV+ASV achieved a 92% SVR12 rate which was unaffected by factors known to attenuate response to interferon.
Experimental Study of the Runaway Current in the J-TEXT Tokamak
Y. H. Luo,Z. Y. Chen,X. Q. Zhang,D. W. Huang,W. Jin,Y. H. Huang,Y. Tang,J. C. Li,R. H. Tong,W. Yan,G. Zhuang 한국물리학회 2014 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.64 No.3
Major plasma disruptions in tokamaks often generate runaway currents, which contain electronswith energies of several tens of megaelectron-volts (MeV). These currents can cause substantialdamage when control is lost and the current hits the limiters or the vessel wall. The interactionbetween the runaway electrons and the impurities inside the plasma results in soft X-ray emission,which can provide detailed information about the runaway generation process and the confinementof runaway electrons. A vertical soft X-ray array at the top of Joint Texas Experimental Tokamak(J-TEXT) was used to study the runaway beams resulting from major disruptions. Runawayelectron production and confinement of runaway current were observed by using soft X-ray images.